Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

EGFR negative

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

EGFR negative	Non Small Cell Lung Cancer	EGFR negative	Non Small Cell Lung Cancer	pembrolizumab + atezolizumab Sensitive: B - Late Trials pembrolizumab + atezolizumab Sensitive : B	pembrolizumab + atezolizumab Sensitive: B - Late Trials pembrolizumab + atezolizumab Sensitive : B
EGFR negative	Non Small Cell Lung Cancer	EGFR negative	Non Small Cell Lung Cancer	anlotinib + sintilimab Sensitive: C2 – Inclusion Criteria anlotinib + sintilimab Sensitive : C2	anlotinib + sintilimab Sensitive: C2 – Inclusion Criteria anlotinib + sintilimab Sensitive : C2
EGFR negative	Non Small Cell Lung Cancer	EGFR negative	Non Small Cell Lung Cancer	anlotinib Sensitive: C2 – Inclusion Criteria anlotinib Sensitive : C2	anlotinib Sensitive: C2 – Inclusion Criteria anlotinib Sensitive : C2
EGFR negative	Non Small Cell Lung Cancer	EGFR negative	Non Small Cell Lung Cancer	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2
EGFR negative	Non Small Cell Lung Cancer	EGFR negative	Non Small Cell Lung Cancer	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3
EGFR negative	Lung Non-Squamous Non-Small Cell Cancer	EGFR negative	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3